Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedMay 08, 2024
DataAggregated Company Financials
Companies7
  • 7D0.5%
  • 3M0.6%
  • 1Y8.1%
  • YTDn/a

Over the last 7 days, the Biotech industry has remained flat, although notably Idorsia gained 16%. As for the the longer term, the industry is up 8.1% over the past 12 months. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 09 May 2024CHF483.5mCHF170.9m-CHF134,968,230.181x-3.6x2.8x
Sat, 06 Apr 2024CHF382.6mCHF67.4m-CHF173,193,075.500.1x-2.2x5.7x
Mon, 04 Mar 2024CHF360.1mCHF55.6m-CHF173,212,672.720.2x-2.1x6.5x
Wed, 31 Jan 2024CHF377.8mCHF317.6m-CHF176,007,021.001.1x-2.1x1.2x
Fri, 29 Dec 2023CHF288.1mCHF317.2m-CHF176,181,463.000.6x-1.6x0.9x
Sun, 26 Nov 2023CHF304.1mCHF318.1m-CHF210,673,204.00n/a-1.4x1x
Tue, 24 Oct 2023CHF252.0mCHF318.1m-CHF212,843,042.00n/a-1.2x0.8x
Thu, 21 Sep 2023CHF274.7mCHF318.5m-CHF219,022,560.00n/a-1.3x0.9x
Sat, 19 Aug 2023CHF509.0mCHF325.8m-CHF175,785,222.00n/a-2.9x1.6x
Mon, 17 Jul 2023CHF315.7mCHF320.3m-CHF179,703,342.00n/a-1.8x1x
Wed, 14 Jun 2023CHF320.9mCHF333.9m-CHF181,118,746.00n/a-1.8x1x
Fri, 12 May 2023CHF369.7mCHF498.9m-CHF18,561,621.001.7x-19.9x0.7x
Sun, 09 Apr 2023CHF407.2mCHF485.0mCHF12.4m1.5x32.8x0.8x
Tue, 07 Mar 2023CHF485.5mCHF493.4mCHF14.5m1.7x33.5x1x
Thu, 02 Feb 2023CHF497.0mCHF493.4mCHF14.5m1.6x34.3x1x
Sat, 31 Dec 2022CHF485.3mCHF493.4mCHF14.5m1.7x33.5x1x
Mon, 28 Nov 2022CHF515.0mCHF493.4mCHF14.5m1.7x35.5x1x
Wed, 26 Oct 2022CHF522.5mCHF509.3mCHF15.9m2x32.9x1x
Fri, 23 Sep 2022CHF519.3mCHF505.5mCHF15.9m1.9x32.6x1x
Sun, 21 Aug 2022CHF518.2mCHF486.5mCHF36.1m1.9x14.3x1.1x
Tue, 19 Jul 2022CHF528.7mCHF491.7mCHF42.2m1.8x12.5x1.1x
Thu, 16 Jun 2022CHF547.5mCHF466.2mCHF82.4m1.9x6.6x1.2x
Sat, 14 May 2022CHF697.6mCHF306.2m-CHF143,600,068.001.9x-4.9x2.3x
Mon, 11 Apr 2022CHF1.1bCHF289.3m-CHF142,900,952.002x-8x4x
Wed, 09 Mar 2022CHF1.2bCHF284.1m-CHF138,704,907.002x-8.9x4.3x
Fri, 04 Feb 2022CHF5.0bCHF317.1m-CHF659,069,116.001.8x-7.6x15.7x
Sun, 02 Jan 2022CHF4.4bCHF315.4m-CHF659,302,924.002x-6.6x13.9x
Tue, 30 Nov 2021CHF3.8bCHF318.9m-CHF658,812,933.001.5x-5.7x11.8x
Thu, 28 Oct 2021CHF4.3bCHF304.5m-CHF641,797,820.002.3x-6.7x14.2x
Sat, 25 Sep 2021CHF5.1bCHF302.0m-CHF635,876,034.001.3x-8x16.8x
Mon, 23 Aug 2021CHF5.3bCHF306.0m-CHF612,309,374.801.1x-8.6x17.2x
Sat, 10 Jul 2021CHF5.8bCHF306.0m-CHF612,309,374.801.1x-9.4x18.8x
Price to Earnings Ratio

-10.8x


Total Market Cap: CHF5.8bTotal Earnings: -CHF535,605,963.80Total Revenue: CHF352.3mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average 5.5x202220232024
Current Industry PE
  • Investors are pessimistic on the Swiss Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 5.2x is higher than the industry's current PS ratio of 2.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 21% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Comparison

How does Swiss Biotech compare with similar industries?

CH Market1.95%
Healthcare0.82%
Biotech0.48%
Biotech0.48%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
IDIA IdorsiaCHF2.1116.5%
+CHF53.6m
-74.1%PS2x
BSLN Basilea PharmaceuticaCHF42.858.5%
+CHF43.1m
-6.7%PE49.5x
KURN Kuros BiosciencesCHF6.601.9%
+CHF4.8m
368.1%PS7.3x
ADXN Addex TherapeuticsCHF0.07320.3%
+CHF1.6m
-44.0%PS5.7x
SANN Santhera Pharmaceuticals HoldingCHF9.290.3%
+CHF339.6k
50.1%PE1.9x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

RLF

CHF1.22

Relief Therapeutics Holding

7D

-1.6%

1Y

-82.6%

BSLN

CHF42.85

Basilea Pharmaceutica

7D

8.5%

1Y

-6.7%

MOLN

CHF3.25

Molecular Partners

7D

-1.2%

1Y

-45.8%

SANN

CHF9.29

Santhera Pharmaceuticals Holding

7D

0.3%

1Y

50.1%

ADXN

CHF0.073

Addex Therapeutics

7D

20.3%

1Y

-44.0%

KURN

CHF6.60

Kuros Biosciences

7D

1.9%

1Y

368.1%

SPEX

CHF0.063

Spexis

7D

7.1%

1Y

-82.0%

OBSN

CHF0.0012

ObsEva

7D

-81.3%

1Y

-98.5%